ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2336

Identification of Osteoporosis As a Reason for Vertebral Fractures in Patients with Rheumatoid Arthritis and Non-Inflammatory Musculoskeletal Diseases – a Comparison between Trabecular Bone Score (TBS) and Bone Mineral Density (BMD)

Bjoern Buehring1, Xenofon Baraliakos1, Julian Thomas2 and Jürgen Braun1, 1Ruhr-University Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Herne, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Identification of osteoporosis as a reason for vertebral fractures in patients with rheumatoid arthritis and non-inflammatory musculoskeletal diseases – A comparison between trabecular bone score (TBS) and bone mineral density (BMD)

Buehring B, Baraliakos X, Thomas J, Braun J. Rheumazentrum Ruhrgebiet, Herne, Germany.

Background/Purpose: Osteoporosis related fractures are common in patients with rheumatoid arthritis (RA). Measurement of bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) alone does not adequately predict fracture risk. Trabecular bone score (TBS) is a surrogate marker for trabecular microarchitecture which independently predicts fracture risk. In this study we assessed the prevalence of low BMD, low TBS and osteoporotic related vertebral fractures in patients with RA in comparison to controls with non-inflammatory musculoskeletal diseases.

Methods: In retrospective study design, we analyzed the data of all patients with available TBS and DXA data presenting to our hospital in the last 5 years. All diagnoses were made by rheumatologists. Comparisons between groups were made by Mann-Whitney-Test and Wilcoxon-Test where appropriate, after adjustment for age, cortisone intake and body mass index.

Results: There were 143 patients with RA (mean age 72.1±11.1 years, 72% female) and 106 controls (mean age 69.6±12.6 years, 74.5% female). Vertebral fractures were found in 36.4% (n=52) RA patients and in 22.6% (n=24) controls (p=0.02). Overall, there were no differences in the mean DXA BMD (for both, spine and hips) and the mean TBS values in all patients. On the other hand, there were statistically more RA patients with low BMD (n=102; 71.3%) and TBS scores (n=125; 87.4%) than controls (n=61; 57.5% and n=79; 74.5%, respectively, p=0.009). In addition, in patients with a vertebral fracture, a low TBS with a normal DXA was more frequently observed in both groups (numerically higher in RA than in controls), while low BMD with a normal TBS was rare (Table). This was not the case in patients without a vertebral fracture.

Conclusion: Low TBS in the setting of normal BMD was found more frequently in patients with vertebral fractures, especially in patients with RA, whereas the reverse is rare. This suggests TBS might prove to be a useful tool for identification of deteriorated bone microarchitecture and strength in patients with vertebral fracture with normal BMD.

Table: Prevalence of low and normal BMD and TBS results in patients with incident vertebral

fractures


Disclosure: B. Buehring, None; X. Baraliakos, AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, and Werfen, 2,AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, and Werfen, 5,AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, and Werfen, 8; J. Thomas, None; J. Braun, Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, 2, 5.

To cite this abstract in AMA style:

Buehring B, Baraliakos X, Thomas J, Braun J. Identification of Osteoporosis As a Reason for Vertebral Fractures in Patients with Rheumatoid Arthritis and Non-Inflammatory Musculoskeletal Diseases – a Comparison between Trabecular Bone Score (TBS) and Bone Mineral Density (BMD) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/identification-of-osteoporosis-as-a-reason-for-vertebral-fractures-in-patients-with-rheumatoid-arthritis-and-non-inflammatory-musculoskeletal-diseases-a-comparison-between-trabecular-bone-sc/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-osteoporosis-as-a-reason-for-vertebral-fractures-in-patients-with-rheumatoid-arthritis-and-non-inflammatory-musculoskeletal-diseases-a-comparison-between-trabecular-bone-sc/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology